The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...

The gene editing tool known as CRISPR-Cas9 is changing what's possible for treating a wide range of diseases caused by ...

A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based gene editing to treat a child ...

Deep-pocketed investors have adopted a bearish approach towards CRISPR Therapeutics (NASDAQ:CRSP), and it's something market players shouldn't ignore. Our tracking of public options records at ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Science and medicine are incredibly amazing. Thanks to modern science and medicine, we now have lifespans far beyond our Dark Age predecessors, living until ripe old age and enjoying the fruits of our ...

Drug resistance has long turned some of the most advanced lung cancer therapies into temporary victories, with tumors ...

Crispr ( CRSP) is said to have attracted takeover interest, according to traders, who cited a Betaville "uncooked' alert that ...

Less flashy, yet more broadly and immediately applicable, were the studies on food, the other stuff of life beyond our DNA.

We expect investors to focus on the sales performance of CRISPR Therapeutics’ CRSP sole-marketed product, Casgevy, and other pipeline updates when the company reports its second-quarter 2025 results.

Scientists used CRISPR to disable the NRF2 gene, restoring chemotherapy sensitivity in lung cancer cells and slowing tumor ...